The trial prompted a now-ongoing prospective study of IV low-molecular-weight iron dextrin, given as a single dose over 1 hour to children and teens. Data on the first 22 patients will soon be presented.
"They all responded, with only some minor reactions," Dr. Buchanan said. "This is very preliminary, and I’m not recommending it. But it may be that someday we can give a single short infusion in the office or clinic and take care of the problem right away."
Dr. Buchanan said he had no relevant financial disclosures.